Wednesday, June 10, 2026

biotech ยท Major Depressive Disorder ยท Schizophrenia ยท NBIX

NEUROCRINE BIOSCIENCES

NEUROCRINE BIOSCIENCES clinical programs โ€” 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

6027 Edgewood Bend Ct, San Diego, California 92130, US HQ
1992 Founded
2,307 Employees
Public company Type
NBIX ยท NYSE Ticker
Company details
Status
Public
HQ
6027 Edgewood Bend Ct, San Diego, California 92130, US
Founded
1992
Employees
2,307
Programs
79
Drugs
28
Patents
111
Intelligence ยท Clinical Programs

NEUROCRINE BIOSCIENCES projects

3 ClinicalTrials.gov programs sponsored by NEUROCRINE BIOSCIENCES.

NEUROCRINE BIOSCIENCES has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Valbenazine

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    approved small molecule active

    3 trials
  2. Valbenazine

    NEUROCRINE BIOSCIENCES INC

    Tardive Dyskinesia (TD)

    approved small molecule completed

    2 trials
  3. Valbenazine Oral Capsule

    NEUROCRINE BIOSCIENCES INC

    Tardive Dyskinesia

    approved small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does NEUROCRINE BIOSCIENCES have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.